Central nervous system demyelination presents substantial diagnostic hurdles in routine neurological practice. Although magnetic resonance imaging and cerebrospinal fluid oligoclonal bands provide critical diagnostic clues, clinicians often require deeper molecular clarity to differentiate multiple sclerosis from neuromyelitis optica spectrum disorder. In this context, advanced CSF peptidomics provides unprecedented insight into native intrathecal proteolysis and post-translational changes. Consequently, analyzing endogenous peptide fragments helps uncover active pathological pathways that conventional assays routinely miss. Therefore, evaluating peptidomic remodeling can refine clinical risk stratification and illuminate early neuroinflammatory cascades.

Overcoming Diagnostic Limits With CSF Peptidomics

Differentiating relapsing-remitting multiple sclerosis from neuromyelitis optica spectrum disorder remains vital because their management pathways diverge substantially. For instance, standard multiple sclerosis therapies can exacerbate disease activity in neuromyelitis optica spectrum disorder, potentially causing devastating neurological deficits. While aquaporin-4 antibody assays assist diagnosis, seronegative cases and atypical presentations frequently complicate clinical decisions. Moreover, conventional cerebrospinal fluid assessments, such as evaluating total protein or oligoclonal bands, reflect generalized neuroinflammation rather than specific pathobiological mechanisms.

To address these diagnostic challenges, researchers evaluated native peptide profiles within cerebrospinal fluid using top-down mass spectrometry. Unlike bottom-up methods that require artificial enzymatic digestion, top-down peptidomic approaches preserve endogenous cleavage patterns and native post-translational modifications. Furthermore, this technique directly captures in vivo proteolytic activity, revealing real-time tissue remodeling within the central nervous system. As a result, clinicians gain access to a dynamic molecular window that mirrors cellular injury and enzymatic dysregulation. Ultimately, this granular understanding can assist physicians in identifying active disease earlier and tailoring immunotherapy more precisely for each distinct patient cohort.

Unraveling the CSF Endopeptidome in Demyelinating Disorders

Recent investigations profiled cerebrospinal fluid from treatment-naïve patients across multiple diagnostic stages. Specifically, these cohorts included clinically isolated syndrome, relapsing-remitting multiple sclerosis, and neuromyelitis optica spectrum disorder. Notably, the investigators also included non-inflammatory neurological controls to benchmark baseline physiological variation. By avoiding confounding immunomodulatory treatments, the research team isolated pristine signatures of intrathecal inflammation and endogenous peptide degradation.

In total, the top-down profiling identified 381 endogenous peptides across these patient groups. Interestingly, a significant proportion of these fragments represented previously unreported sequences and novel post-translational modifications. These endogenous peptides derived primarily from proteins involved in secretory pathways, extracellular matrix integrity, and local neuroimmune communication. For example, researchers detected prominent peptide fragments originating from granin family members, osteopontin, proSAAS, and fibrinogen. Because these precursor molecules control vesicle trafficking and cellular signaling, their altered cleavage reflects targeted enzymatic processing during active demyelination. Consequently, these findings establish the cerebrospinal fluid endopeptidome as an informative molecular layer reflecting active neuroinjury.

Secretogranin-5 Peptide Loss as an MS Biomarker

Among the identified molecular alterations, a newly characterized C-terminal peptide derived from secretogranin-5 demonstrated remarkable clinical significance. Specifically, quantitative peptidomic measurements revealed a progressive, cross-sectional decrease in this peptide from clinically isolated syndrome to established relapsing-remitting multiple sclerosis. Furthermore, secretogranin-5, also known as 7B2, functions as an essential molecular chaperone for prohormone convertase 2 within dense-core neuroendocrine secretory granules.

When investigators applied random forest machine learning algorithms to the dataset, this secretogranin-5 fragment emerged as the single most informative feature for patient classification. Therefore, measuring this fragment may allow clinicians to monitor neuroendocrine secretory failure alongside early neuroaxonal damage. In addition, the gradual depletion of secretogranin-5 fragments suggests that progressive secretory pathway exhaustion accompanies disease evolution. As demyelinating lesions accumulate, impaired peptide processing likely compromises endogenous neuroprotective mechanisms within the central nervous system. Thus, tracking secretogranin-5 peptide kinetics provides valuable diagnostic and prognostic intelligence, potentially offering a surrogate marker for therapeutic response during disease-modifying therapy.

Distinct Peptidomic and Redox Divergence in NMOSD

In contrast to multiple sclerosis, patients diagnosed with neuromyelitis optica spectrum disorder exhibited a profoundly different peptidomic landscape. Specifically, neuromyelitis optica spectrum disorder profiles displayed widespread peptide depletion and a substantially lower representation of oxidized peptide species. Because astrocytic end-foot destruction mediated by complement and aquaporin-4 autoantibodies drives neuromyelitis optica spectrum disorder, the resulting tissue injury differs fundamentally from the oligodendrocyte and myelin pathology characteristic of multiple sclerosis.

Additionally, oxidative post-translational modifications offered compelling discriminatory power between these conditions. In multiple sclerosis, intrathecal inflammation generates substantial reactive oxygen species, which leads to prominent oxidative modifications on peptides derived from fibrinogen and osteopontin. Conversely, neuromyelitis optica spectrum disorder specimens showed markedly attenuated peptide oxidation despite pronounced clinical severity. This biochemical divergence indicates distinct enzymatic microenvironments and redox states within the subarachnoid space. Consequently, evaluating both peptide abundance and oxidative status allows clinicians to separate these two demyelinating conditions with greater diagnostic confidence, particularly when standard serological tests yield borderline results.

Translational Prospects for Clinical Practice

Integrating high-resolution peptidomic profiling into routine diagnostic pathways holds immense potential for modern neuroimmunology. Currently, neurologists rely heavily on magnetic resonance imaging and lumbar punctures to assess oligoclonal bands. However, these traditional tools cannot fully capture dynamic proteolytic remodeling or active oxidative stress pathways. By identifying specific endogenous peptide fragments, peptidomics bridges the gap between static imaging abnormalities and real-time biochemical pathophysiology.

Furthermore, developing targeted liquid chromatography-tandem mass spectrometry assays could soon bring these peptidomic signatures into hospital laboratories. For example, clinicians could use multiplexed peptide panels to monitor therapeutic efficacy, detect subclinical disease activity, and predict impending clinical relapses. Moreover, identifying disturbed prohormone processing and granin dysregulation opens new avenues for neuroprotective therapeutic targets. While large multicenter cohorts must validate these findings in diverse patient populations, the initial evidence confirms that endogenous peptides represent highly informative biosignatures. Ultimately, adopting peptidomic diagnostics will refine clinical decision-making, reduce misdiagnosis rates, and accelerate personalized treatment strategies for complex demyelinating diseases.

How does top-down peptidomics differ from traditional proteomics?

Top-down peptidomics analyzes naturally occurring endogenous peptides without using external enzymatic digestion such as trypsin cleavage. Consequently, this approach directly preserves native post-translational modifications, including oxidative changes and endogenous proteolytic cleavage patterns. In contrast, standard bottom-up proteomics fragments intact proteins into artificial peptides, which destroys crucial information regarding in vivo protease activity. Therefore, top-down peptidomics captures real-time biochemical processes and pathological degradation occurring within the central nervous system.

Why is secretogranin-5 significant in multiple sclerosis?

Secretogranin-5 serves as a crucial molecular chaperone that facilitates prohormone convertase maturation within neuroendocrine secretory granules. Recent research shows that a newly identified C-terminal secretogranin-5 peptide progressively decreases from clinically isolated syndrome to relapsing-remitting multiple sclerosis. Furthermore, machine learning models identified this specific peptide fragment as the most informative marker for patient discrimination. Consequently, its progressive loss reflects neuroendocrine secretory dysfunction and advancing tissue injury during central demyelination.

How does the CSF peptide profile differentiate MS from NMOSD?

Multiple sclerosis exhibits pronounced oxidative post-translational modifications and selective peptide alterations derived from osteopontin and granins, mirroring chronic intrathecal inflammation. In contrast, neuromyelitis optica spectrum disorder displays widespread peptide depletion alongside significantly reduced oxidative modifications, reflecting distinct astrocytic injury rather than typical demyelinating pathways. Consequently, evaluating both endogenous peptide concentrations and redox-dependent modifications provides clear molecular criteria to differentiate these two disorders when standard imaging and serology remain inconclusive.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Contini C et al. Top-Down CSF Peptidomics Reveals Disease-Associated Peptide Signatures and Oxidative Modifications in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Proteomics. 2026 Oct 05. doi: 10.1002/pmic.70188. PMID: 42831274.


2. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27-40.


3. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.


4. Teunissen CE, Malek-Ahmadi M, Blennow K, et al. Cerebrospinal fluid biomarkers in neurodegenerative and neuroinflammatory diseases. Nat Rev Neurol. 2023;19(6):329-346.